Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pharmacy Groups Say Draft Medicaid FULs Could Lead To Rx Access Issues

Executive Summary

Associations representing retail pharmacies say faults in CMS’ draft average manufacturer price-based federal upper limits for multiple source drugs could result in reduced access to drugs by the Medicaid population.

You may also be interested in...



CMS’ Long-Awaited AMP Rule Seeks To Clarify Uncertainties In Affordable Care Act’s Definition

A proposed rule on the calculation of average manufacturer price issued Jan. 27 addresses numerous complex issues for the pharmaceutical industry in its 200 pages, including a proposal that manufacturers report AMP based on their actual sales to retail community pharmacies or to wholesalers for drugs distributed to retail community pharmacies.

A Return To Restricted Pharmacy Networks Leaves NCPA Concerned

In an interview, National Community Pharmacists Association CEO Doug Hoey expresses concern with restricted pharmacy networks in health plans as well as a lack of clarity about those restricted networks on the Medicare Part D Plan Finder website.

Average Manufacturer Prices For Medicaid Drugs Are Publicly Available For First Time

CMS surprises industry by releasing federal upper limit drug pricing files that include weighted average manufacturer prices, without first releasing a rule on the AMP calculation.

Related Content

Topics

UsernamePublicRestriction

Register

OM007836

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel